Motif Bio PLC Exercise of Warrants (8055J)

TIDMMTFB

RNS Number : 8055J

Motif Bio PLC

22 December 2015

Motif Bio plc

("Motif" or the "Company")

Exercise of Warrants

Motif Bio plc (AIM:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announces that the Company will issue 35,925 ordinary shares of 1 penny each ("Option Shares") in settlement of options that have been exercised. The options were exercised at a price of US $0.20 per ordinary share for total consideration of US $7,185.

Admission to trading on AIM ("Admission") of the Option Shares, which will rank pari passu with the existing Ordinary Shares, will be applied for, and it is expected that Admission will become effective and dealings in the new Ordinary Shares will commence on 29 December 2015.

Total Voting Rights

Following Admission, the total issued share capital of the Company will be 108,601,496 Ordinary Shares with one voting right each. The Company does not hold any shares in treasury.

Accordingly, the total voting rights in the Company will be 108,601,496. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure and Transparency Rules of the UK Financial Conduct Authority.

For further information please contact

Enquiries

 
 Motif Bio plc                           info@motifbio.com 
  Graham Lumsden (Chief Executive 
  Officer) 
  David Huang (Chief Medical Officer) 
  www.motifbio.com 
 Zeus Capital Limited (NOMINATED 
  ADVISER and BROKER) 
  Phil Walker/Dan Bate                   +44 (0) 20 
  Dominic Wilson                          3829 5000 
 Northland Capital Partners Limited 
  (BROKER) 
  Patrick Claridge/ David Hignell        +44 (0) 20 
  John Howes/ Mark Treharne (Broking)     7382 1100 
 
                                           +49 (0) 89 
   MC Services AG (TRADE PR)               210 2280 
   Raimund Gabriel                         +44 (0) 207 
   Shaun Brown                             148 5998 
 Plumtree Capital Limited (FINANCIAL 
  ADVISOR)                               +44 (0) 207 
  Stephen Austin                          183 2493 
 Yellow Jersey PR Limited (FINANCIAL 
  PR) 
  Charles Goodwin                        +44 (0) 7747 
  Dominic Barretto                        788 221

Notes to Editors:

Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company has a lead antibiotic candidate, iclaprim, in clinical development and MTF-001, a preclinical stage programme to design a best-in-class dihydrofolate reductase inhibitor (DHFRi).

Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.

This information is provided by RNS

The company news service from the London Stock Exchange

END

LISFEUFAFFISEDE

(END) Dow Jones Newswires

December 22, 2015 02:00 ET (07:00 GMT)

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Ago 2024 a Set 2024